Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2

Status

Completed 16Recruiting 9Active not recruiting 6Terminated 5Unknown 4Withdrawn 2Not yet recruiting 2

Sponsor Class

INDUSTRY 4NIH 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Colorectal Neoplasms 30Carcinoma, Hepatocellular 17Ovarian Neoplasms 14Fallopian Tube Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Neoplasms 8Glioblastoma 7Liver Neoplasms 6Lung Neoplasms 5Colonic Neoplasms 5Breast Neoplasms 5Neoplasm Metastasis 4Carcinoma, Renal Cell 4Brain Neoplasms 4Stomach Neoplasms 3Rectal Neoplasms 3Melanoma 3Carcinoma, Ovarian Epithelial 3Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Nasopharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoid Interstitial Pneumonia 2Colorectal Cancer Metastatic 2Brenner Tumor 2Advanced Solid Tumors 2Adenocarcinoma, Mucinous 2Virus Diseases 1

Interventions

durvalumab 7Bevacizumab 6tremelimumab 3Nivolumab 3lenvatinib 2fludarabine 2Cyclophosphamide 2zimberelimab 1toripalimab 1ropidoxuridine 1relatlimab 1pembrolizumab 1fludarabine phosphate 1atezolizumab 1X-Rays 1Technetium Tc 99m Aggregated Albumin 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Radionuclide Imaging 1Platinum 1Photons 1Paclitaxel 1Observation 1Long-Term Potentiation 1Lidocaine 1Immunotherapy 1Immunoglobulin G 1IMC-001 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Active not recruiting × Liver Neoplasms × Bevacizumab × Clear all
NCT03937830 2026-06-05

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
27 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05211323 2026-06-03

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
88 enrolled
Gastrointestinal

Liver Neoplasms

NCT03778957 2026-04-15

EMERALD-1

AstraZeneca

Phase 3 Active not recruiting
724 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06679985 2026-04-13

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

Coherus Oncology, Inc.

Phase 2 Active not recruiting
72 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06040099 2026-03-19

EMERALD-Y90

AstraZeneca

Phase 2 Active not recruiting
58 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03847428 2026-03-06

EMERALD-2

AstraZeneca

Phase 3 Active not recruiting
908 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡